S&P downgrades Teva amid continued struggles. Embattled generic drug giant Teva issued a sobering, conservative 2018 outlook during its latest earnings call, falling short of analyst expectations. Competition in the generic drug market has been hitting Teva hard, leading to a major management shakeup by new CEO Kare Schultz and massive layoffs as the firm attempts to pay down debt and right its business model. Teva stock is down more than 43% in the past 12 months. ( TheStreet )